Premium
OXPRENOLOL IN THE TREATMENT OF MIGRAINE
Author(s) -
Ekbom Karl,
Zetterman Marianne
Publication year - 1977
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1977.tb01423.x
Subject(s) - oxprenolol , migraine , migraine disorders , medicine , pharmacology , anesthesia , propranolol
Thirty migraine patients received oxprenolol (Trasicor ®), which is an adrenergic beta‐receptor blocking agent with weak beta‐stimulating intrinsic activity. The dosage was 80 mg three times a day. The treatment was given by a double blind cross‐over technique in which the effect was compared with placebo. Each compound was administered for 8 weeks with an intermediate week without medication (wash‐out). Oxprenolol had no significant effects in the prevention of migraine attacks. Our study lends further support to the assumption that differences may exist between different beta‐receptor blocking agents in their effectiveness in migraine prophylaxis.